What We Know About the ALDH3B2 Gene Tweak for Diabetes

A team led by Harvard Medical School reported that silencing a single gene, ALDH3B2, sharply increased the rate at which pancreatic ductal cells convert into insulin-producing cells, according to a study published in Science Translational Medicine and described by Wired. The work targets a longstanding problem in diabetes care: replacing the beta cells that make insulin but are missing or damaged in people with the disease.

What did the researchers find?

A healthy human pancreas contains roughly a billion beta cells, Wired reported, and in diabetes many of those cells stop functioning or disappear. Scientists had previously observed that pancreatic ductal cells occasionally shift into a beta-like state on their own, but the genetic trigger was unknown. Jian Li, a postdoctoral researcher at Harvard Medical School who led the study, said scientists previously had no clue what genes were driving that shift, according to Wired.

How did the gene screen work?

The team ran a genetic screen, a method that disables small stretches of DNA across the genome to see which sections matter for a given process — comparable to removing individual parts from a car engine to learn which ones affect fuel delivery or steering. That screen pointed to ALDH3B2. Without any genetic change, fewer than 1 percent of ductal cells spontaneously took on beta-like traits, Wired reported. When researchers silenced ALDH3B2, that share rose to about 8.5 percent.

What happened after transplant into mice?

The altered human cells were transplanted into diabetic mice, and human insulin began circulating in the animals' blood, according to Wired. Glucose levels in the mice dropped to near-normal, and those effects lasted six weeks in the reported experiments.

Data snapshot

• Baseline spontaneous conversion of ductal cells to beta-like cells: under 1 percent
• Conversion rate after ALDH3B2 was silenced: about 8.5 percent
• Duration of near-normal glucose levels in treated mice: six weeks
• Approximate beta cells in a healthy human pancreas: 1 billion

How does this compare with other diabetes gene therapies?

Other approaches now in development include a clinical trial launched earlier this year that engineers muscle cells to produce insulin, and lab-grown insulin-producing cells transplanted into patients, Wired reported. The transplant method carries a risk of triggering the immune system. The ALDH3B2 approach instead aims to repurpose cells already present in the pancreas by switching off genetic signals that keep them locked in their ductal identity.

What questions remain unanswered?

Wired reported two open issues. First, ALDH3B2 is active in many cell types beyond the pancreas, so any therapy would need to edit only the intended ductal cells to avoid unintended effects elsewhere in the body. Second, researchers still do not fully understand the mechanism by which turning off this gene pushes a ductal cell toward a beta-cell identity — a question the Harvard team has not yet resolved, according to the published study.

The findings mark an early laboratory and animal-model result rather than a treatment ready for testing in people. Wired did not report a timeline for human trials.